Wearable Defibrillator Therapy

ZOLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions, announced that the ZOLL LifeVest® Wearable Defibrillator is now covered by Medical Assistance (MA), Minnesota's Medicaid program. The WCD (LifeVest®, ZOLL, Pittsburgh, PA) was FDA-approved in 2001 as an outpatient device after a clinical trial involving 285 out-of-hospital patients 16 WCDs are intended for use in adult patients that have an increased risk of SCD if an ICD is not warranted.
In conclusion, in this trial, we compared the use of a wearable cardioverter-defibrillator plus guideline-directed medical therapy with guideline-directed Wearable Defibrillator medical therapy alone in patients who presented with an acute myocardial infarction with an ejection fraction of 35% or less.

Six weeks after WCD therapy commenced, rates of depression and anxiety dropped to 7 and 25%, respectively 32 It is not clear if patients recovered their emotional equilibrium as a result of WCD therapy or as a matter of course as they got used to their new identities as cardiac patients.
Dr. Werner Jung, Schwarzwald-Baar Kliniken, Villingen Schwenningen, Germany, and PD Dr. Christian Veltmann, Medizinische Hochschule, Hannover, Germany, will present a symposium entitled New Onset Heart Failure Patients are Different: A Strategy for Managing SCD Risk During Medical Optimization,” Monday, 1 September, 1:00-1:45 p.m., Reykjavik, Village 6, Session #3783.

Others have told Olgin that worrying about an accidental shock makes them anxious; in the study, nine people were shocked when they didn't need to be. And patients sometimes reported their vests emitting alarms when they felt fine — another potential source of stress.
So before he was released from the hospital, he was fitted for a vest equipped with an automatic external defibrillator similar to those found at schools, churches and other public venues to shock someone who's suffered a cardiac arrest back to life.

Although this result is subject to bias, it suggests a benefit to wearing the device (see the Supplementary Appendix ) and implies that low adherence to wearing the device may be a limiting factor in the potential benefit of the wearable cardioverter-defibrillator.
It was designed to test whether this device could effectively reduce sudden death in patients who had recently suffered a heart attack and had reduced heart function (defined as a low ejection fraction of 35 percent or less) where the heart wasn't able to pump sufficient blood to the rest of the body, which is indicative of a sizable heart attack.

Leave a Reply

Your email address will not be published. Required fields are marked *